Panion & Bf Biotech Inc. (1760.TW)
TWD 81.4
(-1.57%)
TWD 81.4
(-1.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 727.83 Million TWD | 50.9% |
| 2022 | 482.33 Million TWD | -4.03% |
| 2021 | 502.56 Million TWD | -59.45% |
| 2020 | 1.23 Billion TWD | 1016.38% |
| 2019 | 111.01 Million TWD | 0.0% |
| 2018 | - TWD | 0.0% |
| 2017 | - TWD | 0.0% |
| 2016 | - TWD | 0.0% |
| 2015 | - TWD | -100.0% |
| 2014 | 1.08 Million TWD | 0.0% |
| 2013 | - TWD | -100.0% |
| 2012 | 339.31 Million TWD | -2.06% |
| 2011 | 346.43 Million TWD | 14.04% |
| 2010 | 303.78 Million TWD | 44.82% |
| 2009 | 209.76 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 745.85 Million TWD | 8.68% |
| 2024 Q1 | 686.3 Million TWD | -5.71% |
| 2023 FY | 727.83 Million TWD | 50.9% |
| 2023 Q4 | 727.83 Million TWD | 11.47% |
| 2023 Q1 | 474.53 Million TWD | -1.62% |
| 2023 Q3 | 652.92 Million TWD | 3.85% |
| 2023 Q2 | 628.72 Million TWD | 32.49% |
| 2022 Q2 | 364.08 Million TWD | -29.46% |
| 2022 Q4 | 482.33 Million TWD | 13.77% |
| 2022 Q1 | 516.16 Million TWD | 2.71% |
| 2022 FY | 482.33 Million TWD | -4.03% |
| 2022 Q3 | 423.95 Million TWD | 16.44% |
| 2021 Q2 | 1.14 Billion TWD | -13.95% |
| 2021 Q3 | 538.49 Million TWD | -52.96% |
| 2021 Q4 | 502.56 Million TWD | -6.67% |
| 2021 FY | 502.56 Million TWD | -59.45% |
| 2021 Q1 | 1.33 Billion TWD | 7.34% |
| 2020 Q3 | 258.98 Million TWD | 50.71% |
| 2020 Q2 | 171.84 Million TWD | 19.89% |
| 2020 Q1 | 143.33 Million TWD | 29.11% |
| 2020 Q4 | 1.23 Billion TWD | 378.54% |
| 2020 FY | 1.23 Billion TWD | 1016.38% |
| 2019 Q2 | 87.94 Million TWD | -4.22% |
| 2019 FY | 111.01 Million TWD | 0.0% |
| 2019 Q3 | 83.71 Million TWD | -4.82% |
| 2019 Q4 | 111.01 Million TWD | 32.61% |
| 2019 Q1 | 91.82 Million TWD | 0.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2018 FY | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 Q2 | - TWD | 0.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2017 Q4 | - TWD | 0.0% |
| 2017 FY | - TWD | 0.0% |
| 2017 Q3 | - TWD | -100.0% |
| 2017 Q2 | 145 Thousand TWD | 0.0% |
| 2017 Q1 | - TWD | 0.0% |
| 2016 Q1 | 10 Million TWD | 0.0% |
| 2016 Q2 | 10 Million TWD | 0.0% |
| 2016 Q4 | - TWD | 0.0% |
| 2016 FY | - TWD | 0.0% |
| 2015 Q1 | 10 Million TWD | 823.36% |
| 2015 FY | - TWD | -100.0% |
| 2015 Q2 | 10 Million TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | -100.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2014 Q2 | 2.5 Million TWD | 0.0% |
| 2014 FY | 1.08 Million TWD | 0.0% |
| 2014 Q4 | 1.08 Million TWD | 0.0% |
| 2014 Q3 | - TWD | -100.0% |
| 2013 Q1 | 357.73 Million TWD | 5.43% |
| 2013 Q2 | 355.18 Million TWD | -0.71% |
| 2013 Q3 | - TWD | -100.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2013 FY | - TWD | -100.0% |
| 2012 Q2 | 330.39 Million TWD | 0.0% |
| 2012 Q3 | - TWD | -100.0% |
| 2012 FY | 339.31 Million TWD | -2.06% |
| 2012 Q4 | 339.31 Million TWD | 0.0% |
| 2011 Q2 | 339.11 Million TWD | 0.0% |
| 2011 FY | 346.43 Million TWD | 14.04% |
| 2011 Q4 | 346.43 Million TWD | 0.0% |
| 2010 Q4 | 303.78 Million TWD | 0.0% |
| 2010 FY | 303.78 Million TWD | 44.82% |
| 2009 FY | 209.76 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 180.83 Million TWD | -302.493% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.94 Billion TWD | 62.58% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.2 Billion TWD | 39.804% |
| GenMont Biotech Incorporation | 58.3 Million TWD | -1148.277% |
| Abnova (Taiwan) Corporation | 7.7 Million TWD | -9345.017% |
| Adimmune Corporation | 3.14 Billion TWD | 76.84% |
| Tanvex BioPharma, Inc. | 1.73 Billion TWD | 57.972% |
| Polaris Group | 1.19 Billion TWD | 39.248% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 74.32 Million TWD | -879.218% |
| PELL Bio-Med Technology Co. Ltd. | 172.55 Million TWD | -321.793% |